DrugDashboards

Liraglutide

Liraglutide · LIRAGLUTIDE 6 mg/mL · Injection, Solution · Subcutaneous · Orbicular Pharmaceutical Technologies Private Limited

NDC 81607-0018-01 · 3 SYRINGE, PLASTIC in 1 CARTON / 3 mL in 1 SYRINGE, PLASTIC · ANDA · View full market →

The short version

7 companies supply this market — a reasonable cushion if one runs into trouble. Historically, drugs in this position went on to a new shortage within 90 days about 0.3% of the time — roughly 2× the typical drug (0.1%).

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

90-day shortage risk (model v2)

0.3%chance of a new FDA shortage posting for liraglutide (injectable) in the next 90 days

sterile injectable · sole-source market · 1 Class I/II recall(s) in 12 months

For scale: the typical drug’s chance is about 0.1% — this one is 2× that.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill · avg $772.57 per prescription
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
ANDA217590
TE code
AP1
Approval date
Jan 14, 2026
Patents / exclusivity
None on file

Shortage history

  • Planned discontinuation — Liraglutide, Injection, 6 mg/1 mL (NDC 0480-7250-46)May 14, 2026
  • Planned discontinuation — Saxenda, Injection, 6 mg/1 mL (NDC 0169-2800-15)Jul 18, 2023

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Liraglutide (Injection, Solution)

LabelerStrengthFirst seenLast seen
Cipla USA Inc.LIRAGLUTIDE 6 mg/mLJul 15, 2026Sep 3, 2026
Orbicular Pharmaceutical Technologies Private LimitedLIRAGLUTIDE 6 mg/mLJul 15, 2026Sep 3, 2026
A-S Medication SolutionsLIRAGLUTIDE 6 mg/mLJul 15, 2026Sep 2, 2026
Biocon Pharma Inc.LIRAGLUTIDE 6 mg/mLJul 15, 2026Sep 2, 2026
Novo Nordisk Pharmaceutical Industries, LPLIRAGLUTIDE 6 mg/mLJul 15, 2026Sep 2, 2026
Teva Pharmaceuticals, Inc.LIRAGLUTIDE 6 mg/mLJul 15, 2026Sep 2, 2026
Hybio Pharmaceutical Co., Ltd. (Pingshan Factory)LIRAGLUTIDE 18 mg/3mLJul 15, 2026Aug 28, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Liraglutide — NDC 81607-0018-01," retrieved September 3, 2026, https://drugdashboards.com/drug/81607001801.

Free to cite with attribution — see how the data is put together.